AstraZeneca PLC is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of prescription medicines across various therapy areas. The company's product portfolio includes: - **Oncology:** Medications like Calquence, Enhertu, Faslodex, Imfinzi, Lynparza, Tagrisso, and Zoladex. - **Cardiovascular, Renal, and Metabolism:** Products such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR - **Respiratory and Immunology:** Treatments including Bevespi/Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris - **Rare Diseases:** Medications like Andexxa/Ondexxya, Soliris, Strensiq, and Ultomiris. - **Other Areas:** The company's marketed products also comprise Synagis for respiratory syncytial virus, Fluenz Tetra/FluMist Quadrivalent for Influenza, Seroquel IR/Seroquel XR for schizophrenia bipolar disease, Nexium, and Losec/Prilosec for gastroenterology, Vaxzevria and Evusheld for covid-19. AstraZeneca serves healthcare providers through a combination of distributors and local representative offices, covering the United Kingdom, Europe, the Americas, Asia, Africa, and Australasia. The company collaborates with industry leaders like Regeneron Pharmaceuticals, Neurimmune AG, Ionis Pharmaceuticals, Proteros Biostructures GmbH, and Sierra Oncology, Inc., to expand its research and development capabilities. Originally known as Zeneca Group PLC, the company changed its name to AstraZeneca PLC in 1999 following a merger. AstraZeneca was incorporated in 1992 and is headquartered in Cambridge, United Kingdom.